Follow The Filings

KURA Kura Oncology Inc.

Health Care, filed as KURA ONCOLOGY INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.3%
  • $1.3M
  • 1 reduce

In 2026 Q2 Nathan Fischel trimmed Kura Oncology.

Who owns this now

Largest portfolio weights among holders, up to 0.3% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Reduce 0.25%

Who owns KURA

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 0.25%, was 0.43% Reduce −48.9% 120,568 $1.3M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by KURA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All KURA insider trades
  • $2.4M bought by 1 insider
  • $456K sold by 1 insider outside a trading plan
  • $2.1M sold by 5 insiders under 10b5-1 plans
  1. Kathleen Ford COO
    Planned sale
    $39K 3,668 shares at $10.75 2.5% of stake
    Traded Sep 29 Filed Sep 29
    ↗
  2. Mollie Leoni Chief Medical Officer
    Planned sale
    $310K 28,802 shares at $10.75 17% of stake
    Traded Sep 29 Filed Sep 29
    ↗
  3. Brian T. Powl Chief Commercial Officer
    Planned sale
    $250K 23,430 shares at $10.69 15% of stake
    Traded Sep 28–29 Filed Sep 29
    ↗
  4. Francis Burrows Chief Scientific Officer
    Sale
    $225K 20,726 shares at $10.83 33% of stake
    Traded Sep 24 Filed Sep 25
    ↗
  5. Troy Edward Wilson CEO
    Buy
    $1.2M 100,000 shares at $12.39 +26% to stake
    Traded Aug 24 Filed Aug 24
    ↗
  6. Brian T. Powl Chief Commercial Officer
    Planned sale
    $52K 4,345 shares at $11.89 2.5% of stake
    Traded Aug 21 Filed Aug 24
    ↗
  7. Teresa Brophy Bair Chief Legal Officer
    Planned sale
    $398K 31,487 shares at $12.63 14% of stake
    Traded Aug 19 Filed Aug 21
    ↗
  8. Troy Edward Wilson CEO
    Buy
    $1.1M 100,000 shares at $11.12 +36% to stake
    Traded Aug 17 Filed Aug 17
    ↗
  9. Mollie Leoni Chief Medical Officer
    Planned sale
    $834K 84,929 shares at $9.82 32% of stake
    Traded Jun 18 Filed Jun 22
    ↗
  10. Brian T. Powl Chief Commercial Officer
    Planned sale
    $110K 10,000 shares at $11.00 5.4% of stake
    Traded May 21 Filed May 22
    ↗
  11. Kathleen Ford COO
    Planned sale
    $20K 2,257 shares at $9.08 1.4% of stake
    Traded May 19 Filed May 20
    ↗
  12. Brian T. Powl Chief Commercial Officer
    Planned sale
    $3,122 339 shares at $9.21 0.2% of stake
    Traded May 19 Filed May 20
    ↗
  13. Teresa Brophy Bair Chief Legal Officer
    Planned sale
    $21K 2,256 shares at $9.38 1% of stake
    Traded May 18 Filed May 20
    ↗
  14. Francis Burrows Chief Scientific Officer
    Sale
    $232K 23,726 shares at $9.78 41% of stake
    Traded Dec 18, 2025 Filed Dec 19, 2025
    ↗
  15. Faheem Hasnain Director
    Planned sale
    $110K 10,000 shares at $10.98 29% of stake
    Traded Dec 9, 2025 Filed Dec 10, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 26 sales to cover taxes, 11 stock grants, and 5 option exercises.

SEC filings

Recent issuer filings from EDGAR, 15 shown.

Filed Form Detail Links
8-K 8.01 Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $53.88M $67.48M
Net income -$152.63M -$173.98M -$278.67M
Net margin * — -322.9% -412.9%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $432.48M $744.83M $708.66M
Total non-current assets * $16.45M $15.33M $29.7M
Total assets $448.94M $760.16M $738.36M
Total current liabilities $35.26M $78.71M $116.97M
Total non-current liabilities * $16.4M $267.81M $447.25M
Total equity $397.27M $413.64M $174.14M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$124.82M $134.32M -$64.06M
Cash from investing $15.56M -$101.59M -$13.1M
Cash from financing $94.78M $154.42M $1.79M
Net change in cash -$14.48M $187.14M -$75.36M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.